OncoMatch/Clinical Trials/NCT06162377
Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.
Is NCT06162377 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Methylnaltrexone for head and neck squamous cell carcinoma.
Treatment: Methylnaltrexone — To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Lab requirements
Kidney function
chronic kidney disease defined as a eGRF <60 ml/mim [excluded]
Liver function
liver disease defined as transaminitis > 2 folds from normal levels, cirrhosis and hyperbilirubinemia > 2 folds from normal levels [excluded]
Participants with uncontrolled intercurrent illness, including chronic kidney disease defined as a eGRF <60 ml/mim, and liver disease defined as transaminitis > 2 folds from normal levels, cirrhosis and hyperbilirubinemia > 2 folds from normal levels
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify